全文获取类型
收费全文 | 5652篇 |
免费 | 295篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 133篇 |
妇产科学 | 166篇 |
基础医学 | 775篇 |
口腔科学 | 63篇 |
临床医学 | 549篇 |
内科学 | 1378篇 |
皮肤病学 | 88篇 |
神经病学 | 752篇 |
特种医学 | 112篇 |
外科学 | 538篇 |
综合类 | 23篇 |
一般理论 | 2篇 |
预防医学 | 284篇 |
眼科学 | 62篇 |
药学 | 377篇 |
中国医学 | 15篇 |
肿瘤学 | 628篇 |
出版年
2023年 | 44篇 |
2022年 | 67篇 |
2021年 | 133篇 |
2020年 | 91篇 |
2019年 | 112篇 |
2018年 | 142篇 |
2017年 | 111篇 |
2016年 | 121篇 |
2015年 | 132篇 |
2014年 | 184篇 |
2013年 | 249篇 |
2012年 | 358篇 |
2011年 | 366篇 |
2010年 | 181篇 |
2009年 | 213篇 |
2008年 | 361篇 |
2007年 | 356篇 |
2006年 | 371篇 |
2005年 | 353篇 |
2004年 | 298篇 |
2003年 | 277篇 |
2002年 | 224篇 |
2001年 | 124篇 |
2000年 | 124篇 |
1999年 | 103篇 |
1998年 | 61篇 |
1997年 | 56篇 |
1996年 | 52篇 |
1995年 | 49篇 |
1994年 | 41篇 |
1993年 | 33篇 |
1992年 | 58篇 |
1991年 | 58篇 |
1990年 | 47篇 |
1989年 | 44篇 |
1988年 | 59篇 |
1987年 | 44篇 |
1986年 | 32篇 |
1985年 | 24篇 |
1984年 | 26篇 |
1983年 | 18篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1979年 | 28篇 |
1978年 | 15篇 |
1977年 | 10篇 |
1974年 | 11篇 |
1972年 | 8篇 |
1969年 | 14篇 |
1967年 | 7篇 |
排序方式: 共有5978条查询结果,搜索用时 15 毫秒
81.
82.
We present a 70-year-old woman with pre-B acute lymphoblastic leukemia in whom serial imaging studies showed the development
of multiple vertebral collapse, and communicating superior and inferior Schmorl’s nodes creating a longitudinal channel (”tunneling”
Schmorl’s nodes) through the anterior aspect of T12 to L3 vertebral bodies of her osteoporotic thoracolumbar spine. This was
observed after achieving complete remission of the disease and during maintenance therapy. The finding is felt to be secondary
to iatrogenic exacerbation of osteoporosis.
Received: 26 May 2000 Revision requested: 23 June 2000 Revision received: 10 July 2000 Accepted: 13 July 2000 相似文献
83.
84.
This paper presents a cross-sectional survey of subjective quality of life in a sample of 40 Italian patients with disabling mental disorders living in the community. The patients self-rated their quality of life by the Satisfaction with Life Domains Scale. They were satisfied in relation to basic needs, such as housing, food or clothing and appreciated to some extent the services received, but were very unhappy about their income and their intimate sexual relationships. This Italian sample appeared less satisfied than most samples of people with severe mental disorders investigated by the same instrument in other countries. This may be related to the high level of psychopathology and disability shown by patients for whom survival in the community is in itself an achievement. However, lack of money and poor sexual life are common concerns of long-term mentally ill. How to address such problems is a major challenge for community psychiatric services. 相似文献
85.
Mitral homograft replacement of tricuspid valve in children 总被引:2,自引:0,他引:2
86.
Riccardo Valdagni Corrado Italia Paolo Montanaro Angelo Lanceni Paola Lattuada Tiziana Magnani Claudio Fiorino Alan Nahum 《Radiotherapy and oncology》2005,75(1):74-82
BACKGROUND AND PURPOSE: The objectives of the current study were to compare genito-urinary (GU) and gastro-intestinal (GI) toxicities as well as biochemical control (bRFS) in prostate cancer, utilizing conventional (2.0 Gy daily) (STD) or hyperfractionated (HFX) conformal irradiation (CRT). HFX (1.2 Gy BID) was chosen as a radiobiological method to try to reduce long term sequelae without compromising local control. PATIENTS AND METHODS: Three-hundred-and-seventy consecutive patients (pts) entered this prospective, non-randomized trial in the period January 1993-January 2003; 209 were treated with STD and 161 with HFX CRT. All were evaluable for acute toxicity analysis, 179 (STD) and 151 pts (HFX) being evaluable for late sequelae and bRFS analyses. Pt characteristics were not statistically different in the two groups. CRT consisted of a 4-field technique for prostate and/or pelvic nodes and a 5-field boost with rectal shielding. Median doses were 74 and 79.2 Gy for STD and HFX patients respectively, the latter dose being isoeffective for tumour control assuming alpha/beta=10 (EQD(2)=73.9 Gy). Median follow-up was 29.4 months (25.2 mos for STD; 37.7 mos for HFX; P<0.01). The two regimens were compared in terms of acute and late GU and GI toxicities and 5-year bRFS by univariate and multivariate analyses. RESULTS: Acute grade> or =2 GU toxicity was higher in the STD group (48.6% versus 37.3% in HFX, P=0.03), while no significant difference was found for acute GI toxicity. Late grade> or =2 GU and GI toxicities were lower in the HFX group (5-year actuarial rate: GU: 10.1% versus 20.3%, P=0.05; GI: 6.0% versus 10.6%, P=0.18). Five-year bRFS were 70% (+/-13.8%, 95% CI) and 82.6% (+/-7.2%) for STD and HFX, respectively (P=0.44); a trend favouring HFX was found in the subgroup of pts who did not receive hormonal therapy (5-year bRFS: 85.9%+/-12.4% versus 63.9%+/-23.8%, P=0.15). Multivariate analysis revealed only risk groups and age statistically related to bRFS but not fractionation regimen. Using the Nahum-Chapman TLCP model and prostate parameter set, which includes hypoxia, the TLCPs are approximately equal for the two regimens, whereas assuming alpha/beta=1.5 and no hypoxia we obtain 73% for the STD group but only 36% for the HFX group. CONCLUSIONS: As expected from radiobiological considerations, HFX reduces GI and GU late toxicities. Concerning early bRFS, our clinical findings suggest that HFX is no less effective than STD when delivering an isoeffective (alpha/beta=10) dose. Despite the relatively short follow-up, this result appears to be inconsistent with a low alpha/beta ratio for prostate cancer. 相似文献
87.
Thomas J Cook Shanya Edwards Charlene Gyemah Manoj Shah Indu Shah Tiziana Fox 《Journal of the American Pharmacists Association》2004,44(5):583-586
OBJECTIVE: To determine the weight variation and calculated dosing variability of tablet fragments upon splitting unscored cyclobenzaprine hydrochloride 10 mg tablets using two common tablet splitting devices. DESIGN: Comparative pharmaceutics study. SETTING: Pharmacy school laboratory. PARTICIPANTS: Not applicable. INTERVENTIONS: Unscored cyclobenzaprine hydrochloride 10 mg tablets from one generic manufacturer were split with a tablet splitter or a kitchen knife by a licensed pharmacist and two doctor of pharmacy students (n = 15 tablets for each method per participant). MAIN OUTCOME MEASURES: Fragment weights (FWs) were compared with the theoretical weights (TWs), which were calculated as one half of the mean weight of the tablets used in each part of the experiment; means, relative standard deviations (RSDs), and percentages of TW were also calculated. RESULTS: The mean weight before splitting the 45 tablets with the tablet splitter was 136.6 +/- 2.1 mg (TW = 68.3 mg). The mean FW after splitting was 67.9 +/- 7.9 mg. The RSD of 11.6% corresponded to a range of 69.4% to 130.2% of the TW and an estimated drug content of the split fragments between 3.47 mg and 6.51 mg. The mean weight before splitting the 45 tablets cut with a kitchen knife was 136.6 +/- 2.0 mg (TW = 68.3 mg). The mean FW was 68.0 +/- 15.7 mg with a RSD of 23.2%, corresponding to a range of 49.9% to 149.5% of the TW and an estimated drug content of the split fragments between 2.49 mg and 7.48 CONCLUSION: Tablet fragments obtained after splitting this generic cyclobenzaprine 10 mg product varied considerably in weight and estimated drug content. Accordingly, splitting cyclobenzaprine 10 mg tablets to achieve 5 mg doses could result in unpredictable dosing and therapeutic response. 相似文献
88.
Sara Pilotto Antonio Rossi Tiziana Vavalà Alessandro Follador Marcello Tiseo Domenico Galetta Alessandro Morabito Massimo Di Maio Olga Martelli Orazio Caffo Pier Luigi Piovano Diego Cortinovis Nicoletta Zilembo Clelia Casartelli Giuseppe Luigi Banna Antonio Ardizzoia Maria Luisa Barzelloni Alessandra Bearz Silvia Novello 《Clinical lung cancer》2018,19(1):93-104
Background
Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a “real-life” Caucasian EGFR-mutated non-small-cell lung cancer (NSCLC) population. The sharing of multi-institutional experiences represents a crucial strategy to enrich knowledge about uncommon EGFR mutations. Therefore, we performed a post hoc analysis of the BE-POSITIVE study.Patients and Methods
Data of advanced NSCLC patients with uncommon EGFR mutations who received first-line first-generation EGFR-TKIs in 24 Italian Hospitals were collected. In this analysis we aimed to evaluate overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) of EGFR-TKIs in NSCLC patients harboring uncommon EGFR mutations.Results
Thirty-five patients harboring uncommon EGFR mutations (any mutation other than deletion 19 or substitution of leucine by arginine at codon 858) were included of the original 312 EGFR-mutated cases. Most of them were female (n = 20, 57.1%), former smokers (n = 23, 65.7%), with adenocarcinoma (n = 31, 88.6%). The most frequent EGFR mutations were G719X (n = 6, 17.2%) and L861Q (n = 5, 14.2%). The population presented an ORR of 25.7%, a median PFS of 5.19 months, and a median OS of 14.49 months. When stratified according to type of EGFR mutation, median OS ranged from 3.65 months for unspecified mutations to 21.29 for double EGFR mutations. Median PFS ranged from 1.77 months for unspecified mutations to 20.83 months for concomitant EGFR-anaplastic lymphoma kinase alteration. ORR varied from 0% in exon 18, 20 and double gene alteration to 66.6% in exon 19.Conclusion
Our study supports the existence of a strong outcome heterogeneity within patients harboring uncommon EGFR mutations, which needs to be clarified to achieve a real personalized treatment strategy. 相似文献89.
Metformin Decreases Circulating Androgen and Estrogen Levels in Nondiabetic Women With Breast Cancer
Carlo Campagnoli Franco Berrino Elisabetta Venturelli Chiara Abbà Nicoletta Biglia Tiziana Brucato Patrizia Cogliati Saverio Danese Michela Donadio Gianna Zito Patrizia Pasanisi 《Clinical breast cancer》2013,13(6):433-438
IntroductionDiabetic patients treated with metformin have a lower risk of developing BC or a better BC prognosis. Metformin might reduce cancer growth through direct antiproliferative effects or through indirect mechanisms, particularly the reduction of insulin. In a randomized study on nondiabetic BC patients in natural menopause with high testosterone levels, we observed a significant decrease in insulin and in testosterone levels with metformin 1500 mg/d compared with 1000 mg/d. We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones.Patients and MethodsOne hundred twenty-four eligible women were initially invited to take metformin 500 mg/d for 3 months. The 108 women who completed the first 3 months continued the study using 1000 mg/d for 1 month. The women were then randomized into 2 groups, and, for the subsequent 5 months, 1 group increased the dose to 1500 mg/d, and the other group continued with 1000 mg/d.ResultsNinety-six women completed the study, 43 receiving metformin 1500 mg/day, and 53 receiving 1000 mg/day. The women receiving 1500 mg/d showed a greater and significant reduction of free testosterone (?29%) and estradiol (?38%), a borderline significant reduction of estrone and insulin-like growth factor-1, and a nonsignificant reduction of androstenedione. They also showed a nonsignificant increase of dehydroepiandrosterone sulfate.ConclusionMetformin does not interfere with the production of dehydroepiandrosterone sulfate. Besides, it decreases estradiol levels, basically through the reduction of testosterone. These hormonal changes might have clinical relevance. 相似文献
90.
Luisa Carbognin Cristina Accetta Danilo Di Giorgio Paola Fuso Margherita Muratore Giordana Tiberi Francesco Pavese Tatiana DAngelo Alessandra Fabi Diana Giannarelli Alba Di Leone Stefano Magno Giorgia Garganese Alejandro Martin Sanchez Daniela Andreina Terribile Gianluca Franceschini Riccardo Masetti Giovanni Scambia Ida Paris 《Current oncology (Toronto, Ont.)》2022,29(10):7218
The prevention of chemotherapy-induced alopecia still represents an urgent need for every day clinical practice. In this regard, this prospective single-center study included breast cancer (BC) patients who underwent a scalp cooling device (Dignicap®) during (neo)adjuvant chemotherapy with the aim to evaluate the efficacy and safety of this device in preventing alopecia. One hundred and seventy-eight patients (median age 43 years) were enrolled. The chemotherapy regimen included anthracycline and taxane-based chemotherapy (68.1%), docetaxel and cyclophosphamide (25.8%), anthracycline and taxane-based plus carboplatin (3.9%), and paclitaxel alone (2.2%). In 25.3% of cases, a dose dense schedule was used. Overall, the success rate was 68.0%: 100% in paclitaxel alone, 87.0% in docetaxel-cyclophosphamide, 59.5% in anthracycline and taxane, and 71.4% in the sequential regimen plus carboplatin group (anthracycline and taxane-based chemotherapy versus taxane-based chemotherapy, p ≤ 001. No difference in terms of hair preservation between dose-dense or standard schedule was found (p = 0.557). Early discontinuation of the scalp cooling was observed in 50 patients (28.1%). Although 138 patients (77.5%) experienced adverse events, 70.2% of patients were satisfied with this device. In conclusion, this large prospective study confirmed the helpful effect of the scalp cooling system in preventing alopecia in BC patients also undergoing sequential anthracyclines and taxane-based chemotherapy. 相似文献